

Antibiotics and experimental control of infection

Juan Segurola

Core question

How did antibiotics transform infection from a condition that medicine could sometimes prevent or contain into one that could be experimentally targeted with chemicals, while simultaneously creating new evolutionary and public-health problems?

Historical and evolutionary context

By the early twentieth century, germ theory, antisepsis and vaccination had established that microorganisms could cause disease and that transmission could sometimes be interrupted. Yet many established bacterial infections remained difficult or impossible to treat once they were inside the body. Paul Ehrlich's chemotherapy programme and arsphenamine in 1910 showed that selective chemical intervention was possible. From 1932 to 1935, Gerhard Domagk's work on Prontosil and the sulfonamides established the first effective systemic antibacterial chemotherapy, before penicillin was developed into a scalable therapeutic system. The decisive antibiotic transition therefore came through a distributed chain rather than one observation. Alexander Fleming reported the antibacterial action of a *Penicillium* culture in 1929. The Oxford group led by Howard Florey and Ernst Chain converted penicillin into a reproducible experimental and therapeutic system in 1940–1941, while wartime fermentation and purification programmes made supply scalable.

What could communities know before this transition?

Clinicians could diagnose many infections, isolate bacteria, use antiseptics on surfaces and wounds, and deploy vaccines against selected diseases. PIO-069 had already linked laboratory microbiology to causal germ proof. The limitation was intervention after systemic infection: an agent useful on a bench or skin was not automatically safe, stable, bioavailable or producible enough for internal therapy.

What changed?

Antibacterial activity became an experimentally transferable intervention

Fleming's 1929 report showed that a mould product inhibited susceptible bacteria. The observation was important but did not by itself create a practical drug. In 1940 Chain, Florey, Gardner, Heatley, Jennings, Orr-Ewing and Sanders showed therapeutic effects in infected mice, turning penicillin into a controlled chemotherapeutic experiment. In 1941 Abraham and colleagues reported purification, pharmacology and early human use.

Production became part of the evidence system

A compound that works only in a small culture dish cannot transform medicine. Deep-tank fermentation, strain selection, extraction, assay and standardisation during the 1940s made dose, purity and availability part of the therapeutic system. Industrial microbiology therefore became an epistemic infrastructure as well as a manufacturing technology.

Resistance appeared as part of the same transition

Resistance was not a surprise invented decades later. Abraham and Chain reported a bacterial enzyme able to destroy penicillin in 1940, before mass civilian use. Antibiotics therefore created a new experimental capability and a new selective environment at the same time.

Why could this capability emerge?

The transition depended on germ theory, culture methods, animal models, organic and biological chemistry, hospital observation, assay techniques, refrigeration, fermentation engineering and wartime coordination among universities, governments and industry. It also depended on the ability to compare treated and untreated outcomes rather than rely on anecdotal recovery.

What later forms of knowledge did it enable?

Antibiotics reshaped surgery, intensive care, tuberculosis treatment and the management of bacterial disease. They also helped make controlled therapeutic trials more consequential because drug effects could be large enough to measure against defined clinical endpoints. The resistance problem later connected microbiology to evolution, surveillance and stewardship.

New limits and risks

An effective antibiotic can select for resistant organisms, disturb microbial communities, cause toxicity or allergy, and encourage treatment without adequate diagnosis. Population-level benefit therefore depends on dose, adherence, infection control and stewardship. The ability to kill susceptible bacteria is not equivalent to the ability to eradicate infection safely or indefinitely.

What changed in the architecture of knowledge?

Medicine gained a **molecule-to-organism intervention loop**: isolate or identify a causal organism, test an inhibitory agent, measure therapeutic effect, refine production and dosing, and monitor failure. Causal microbiology became experimentally coupled to treatment.

Loss, exclusion and uncertainty

Hero narratives often reduce the transition to Fleming's 1928 observation. That erases the Oxford team's biochemical, physiological and clinical work, the contributions of Norman Heatley and others to extraction and assay, industrial scale-up, and the labour of patients, technicians and factory workers. It also risks treating resistance as a later misuse rather than a biological consequence visible from the beginning.

Dependency map

- INDIRECT ← PIO-058 From variolation to vaccination
- DIRECT ← PIO-069 Pasteur, Lister and Koch: from antiseptic intervention to germ proof
- INDIRECT → PIO-085 Randomised trials and statistical inference
- INDIRECT → PIO-086 Research ethics, consent and the limits of permissible inquiry

References

1. Fleming, A. "On the Antibacterial Action of Cultures of a *Penicillium*, with Special Reference to their Use in the Isolation of *B. influenzae*." *British Journal of Experimental Pathology* 10(3), 226-236 (1929).
2. Chain, E., Florey, H. W., Gardner, A. D., Heatley, N. G., Jennings, M. A., Orr-Ewing, J. & Sanders, A. G. "Penicillin as a Chemotherapeutic Agent." *The Lancet* 236(6104), 226-228 (1940). DOI: 10.1016/S0140-6736(01)08728-1.
3. Abraham, E. P., Chain, E., Fletcher, C. M., Gardner, A. D., Heatley, N. G., Jennings, M. A. & Florey, H. W. "Further Observations on Penicillin." *The Lancet* 238(6155), 177-189 (1941). DOI: 10.1016/S0140-6736(00)72122-2.
4. Abraham, E. P. & Chain, E. "An Enzyme from Bacteria able to Destroy Penicillin." *Nature* 146, 837 (1940). DOI: 10.1038/146837a0.